AVLN Avalyn Pharma Inc. Insider Trading

Novo Holdings, a 10% owner, acquires 3.9M shares via conversion and open-market purchase; part of multi-insider buying cluster in newly listed stock.

Novo Holdings, an institutional holder with significant ownership, made a substantial acquisition combining a share conversion and open-market purchase totaling nearly four million shares. This transaction is noteworthy in part because it occurred alongside purchases by two other insiders within a two-week window—a pattern that stands out given the stock's very recent listing status. The stock is currently trading at its 52-week high following its IPO launch, which makes this accumulation at peak pricing somewhat unusual: institutional investors and insiders typically build positions during pullbacks rather than at the upper end of trading range. Novo's track record shows prior open-market purchases, making this part of an existing pattern of accumulation at this company rather than a first-time entry. The company fundamentals and operational trajectory warrant review alongside this large institutional commitment to assess whether the timing reflects conviction in long-term positioning or simply routine portfolio mechanics following the listing event.

SR ONE CAPITAL MANAGEMENT buys 555,555 shares ($9,999,990) at $18.00; holdings nearly double to 1.12M in 2-day-old listing

SR ONE CAPITAL MANAGEMENT, a 10% shareholder, executed 2 separate purchases totaling 555,555 shares for $9,999,990.00 at $18.00 on 2026-05-01, doubling its stake from 566,532 shares to 1,122,087 shares (a +98.1% increase). The transaction occurred on a RECENT LISTING stock (2 trading days post-IPO), where the current market price of $29.84 represents a 65.8% premium to the purchase price, though meaningful historical context is unavailable at this stage. A CLUSTER pattern is present: 2 other insiders also bought within the past 14 days, indicating coordinated conviction at the board/executive level. The DERIVATIVE-CONVERSION FLAG indicates this filing contains a conversion of derivative securities, and the insider's full position resides in Table II (not yet populated in our database), so the post-transaction figure of 1.12M shares does not necessarily represent the insider's total economic position.

Director Jill Carroll buys 277,778 shares of AVLN at $18.00 ($5.0M); cluster of 2 other insiders also buying

Director Jill Carroll purchased 277,778 shares at $18.00 on 2026-05-01 for $5,000,004.00, increasing her holdings by 14.6% to 2,186,562 shares post-transaction. This purchase occurs in the context of a cluster buy pattern, with 2 other insiders also acquiring shares within the past 14 days. The filing also references derivative securities conversions (Table II), indicating this director holds a broader position than the Table I equity shares alone. The substantial $5.0M buy into a recently listed stock (2 trading days old) by multiple insiders within a tight timeframe merits investor attention as a potential signal of insider confidence in the early-stage public position.